August 07, 2022
Article
Comparable outcomes seen with sintilimab vs pembrolizumab in patients with treatment-naïve metastatic non–small cell lung cancer.
June 09, 2022
Article
The addition of tucatinib to standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer will be examined in the ongoing phase 3 HER2CLIMB-05 trial.
June 07, 2022
Article
Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.
June 06, 2022
Article
Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.
June 05, 2022
Article
In elderly frail patients with relapsed/refractory multiple myeloma, treatment with ixazomib plus daratumumab achieved favorable response rates.
May 18, 2022
Article
An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,